Swissmedic fast-tracking Novartis Sandoz Hydroxychloroquine for use in Switzerland:

The pharmaceutical company Novartis announced a donation of a ‘substantial amount’ of hydroxychloroquine to treat hospitalized COVID-19 disease patients in Switzerland.

Switzerland is the second country in the world after the USA, and the first in Europe, to receive a donation of this medication.

The aim of the donation is to enable patients to access to potential treatment while also advancing clinical research, said Novartis in a April 3, 2020, press release.

The new treatment protocol issued by the Swiss Society for Infectious Diseases (SSI) includes hydroxychloroquine among the recommended treatments for hospitalized patients infected with COVID-19.

Currently, the approval is valid for the treatment of malaria and autoimmune diseases.

The drug will be used for the treatment under controlled medical supervision.

The Swiss regulatory authority, Swissmedic, responded quickly to the SSI’s treatment recommendation, fast-tracking the procedure to license Novartis / Sandoz’s drug for use on the Swiss market.

“This is a fantastic initiative that aims to help COVID-19 patients around the world, including in Switzerland, by getting a potentially effective drug to them quickly,” says Professor Manuel Battegay, Head Physician Infectious Diseases & Hospital Hygiene, University Hospital Basel, who is a key contributor to the nationwide therapeutic concepts for COVID-19 patients involving hydroxychloroquine.

Read the full article here: https://www.coronavirustoday.com/swissmedic-fast-tracking-novartis-sandoz-hydroxychloroquine-use-switzerland

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »